SCHEMBL29728046

SCHEMBL29728046

Cn1cc2c(Nc3ccccc3C(=O)Nc3cccc(C(F)(F)F)c3)nc(-c3cnccn3)nc2n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 3/20 0.64
▸ EGFR P00533 3/20 0.64
▸ PDGFRB P09619 3/20 0.64
▸ ESYT2 A0FGR8 2/20 0.64
▸ NBAS A2RRP1 2/20 0.64
▸ CNOT1 A5YKK6 2/20 0.64
▸ TBKBP1 A7MCY6 2/20 0.64
▸ AGPS O00116 2/20 0.64
▸ MYO1F O00160 2/20 0.64
▸ SNAP23 O00161 2/20 0.64
▸ AP3B1 O00203 2/20 0.64
▸ PSMD12 O00232 2/20 0.64
▸ BMPR1B O00238 2/20 0.64
▸ PGRMC1 O00264 2/20 0.64
▸ CLIC1 O00299 2/20 0.64
▸ CDC7 O00311 2/20 0.64
▸ IPO5 O00410 2/20 0.64
▸ PLK4 O00444 2/20 0.64
▸ COXFA4 O00483 2/20 0.64
▸ NOP56 O00567 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29728052 0.89 BRAF (0.81) ABL1EGFRPDGFRBESYT2NBAS
SCHEMBL24532038 0.89 BRAF (0.81) ABL1EGFRPDGFRBESYT2NBAS
SCHEMBL29728047 0.87 ABL1 (0.63) ABL1EGFRPDGFRBESYT2NBAS
SCHEMBL29931136 0.78 ABL1 (1.00) ABL1EGFRPDGFRBESYT2NBAS
SCHEMBL16111548 0.78 ABL1 (1.00) ABL1EGFRPDGFRBESYT2NBAS
SCHEMBL4699140 0.78 BRAF (0.80) ABL1EGFRPDGFRBESYT2NBAS
SCHEMBL24532075 0.77 BRAF (0.89) ABL1EGFRPDGFRBESYT2NBAS
SCHEMBL4696222 0.75 BRAF (0.72) ABL1EGFRPDGFRBESYT2NBAS
SCHEMBL15529261 0.71 RXFP1 (1.00) BRAFRXFP1CSF1RMEN1TSHR
SCHEMBL15528884 0.70 RXFP1 (1.00) RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486270-B2 Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-12-02 — — US disclosed
US-20220194943-A1 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2022-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486270-B2 Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder EPHA1, EPHB2, EPHB1 ABL1 75/4885EGFR 27/4885PDGFRB 658/4885
US-20220194943-A1 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER EPHA1, EPHB2, EPHB1 ABL1 75/4885EGFR 27/4885PDGFRB 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback